# Core-003

> **NIH NIH U54** · INDIANA UNIVERSITY INDIANAPOLIS · 2021 · $1,136,511

## Abstract

PROJECT SUMMARY OVERALL COMPONENT
Alzheimer's disease (AD) is a major cause of dementia, disability and death in the elderly. Despite recent
advances in our understanding of basic biological mechanisms underlying AD, we do not yet know how to
prevent AD or have an approved disease modifying intervention. Both are essential to slow or stop the growth
in dementia prevalence. The National Alzheimer's Project Act (NAPA) seeks to prevent and effectively treat AD
by 2025 through innovative research on etiology, early detection, and therapeutics. In support of NAPA's goals,
one of the targeted areas of research identified at the NIA sponsored 2015 Alzheimer's Disease Research
Summit was the development of the next generation of animal models of AD that will prove more predictive in
preclinical studies and thus accelerate the drug testing pipeline. While our current animal models of AD have
provided multiple novel insights into AD disease mechanisms, thus far they have not been successfully utilized
to predict the effectiveness of therapies that have moved into AD clinical trials. The Indiana University
(IU)/Jackson Laboratory (JAX) Alzheimer's Disease Precision Models Center (IU/JAX ADPMC) will
leverage IU's strengths in neurodegenerative research including 25 years as an NIA-supported
Alzheimer's Disease Center (ADC) and considerable expertise in preclinical drug testing with JAX's eight
decades of expertise in mammalian genetics and disease modeling to develop, validate and disseminate
new, precise animal models of Alzheimer's disease (AD). In addition, the IU/JAX ADMPC contains Sage
Bionetworks to provide expertise in data organization and dissemination. The IU/JAX ADPMC brings
together an international, multi-disciplinary team—including geneticists and genetics technology experts,
quantitative and computational biologists, clinical experts in AD and neuroimaging, pharmacologists and
world leaders in the development of precision animal models of disease—that possesses the collective
ability to foresee disease modeling needs as they emerge on the international stage. This will allow the
IU/JAX ADPMC to serve the AD scientific community effectively and efficiently. The IU/JAX ADPMC will
generate new AD modeling processes and pipelines, data resources, research results and models that
will be swiftly shared through JAX's and Sage's proven dissemination pipelines and through the NIA-
supported AD Centers, academic medical centers, research institutions and the pharmaceutical industry
worldwide. Ultimately, this will accelerate the application of advances in animal models for the greatest
possible medical benefit. The Specific Aims of the IU/JAX ADPMC are:
1. Maximize Human Datasets to Identify Putative Variants, Genes and Biomarkers for AD.
2. Generate and Characterize the Next Generation of Mouse Models of AD.
3. Validate the Next Generation of Mouse Models of AD and Develop a Preclinical Testing Pipeline.
!

## Key facts

- **NIH application ID:** 10474014
- **Project number:** 4U54AG054345-06
- **Recipient organization:** INDIANA UNIVERSITY INDIANAPOLIS
- **Principal Investigator:** Gregory W Carter
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,136,511
- **Award type:** 4N
- **Project period:** 2016-09-30 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10474014

## Citation

> US National Institutes of Health, RePORTER application 10474014, Core-003 (4U54AG054345-06). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10474014. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*